UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings

Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for.

UFP Technologies beat analysts’ revenue expectations by 9.6% last quarter, reporting revenues of $145.2 million, up 44% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ EPS estimates.

Is UFP Technologies a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting UFP Technologies’s revenue to grow 39.6% year on year to $141.7 million, improving from the 11.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.14 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. UFP Technologies has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 5.7% on average.

Looking at UFP Technologies’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Azenta delivered year-on-year revenue growth of 4.1%, beating analysts’ expectations by 1.1%, and Charles River Laboratories reported a revenue decline of 1.1%, topping estimates by 2.3%. Azenta traded up 4% following the results while Charles River Laboratories was also up 5.2%.

Read our full analysis of Azenta’s results here and Charles River Laboratories’s results here.

Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the drug development inputs & services stocks have shown solid performance, the group has generally underperformed, with share prices down 5.3% on average over the last month. UFP Technologies is down 12.9% during the same time and is heading into earnings with an average analyst price target of $381 (compared to the current share price of $252).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.